###begin article-title 0
Ligand Modulated Antagonism of PPARgamma by Genomic and Non-Genomic Actions of PPARdelta
###end article-title 0
###begin p 1
Conceived and designed the experiments: MCUG DK CNP. Performed the experiments: MCUG DK. Analyzed the data: MCUG DK CNP. Wrote the paper: MCUG CNP.
###end p 1
###begin p 2
Current address: Department of Laboratory Medicine, Division of Medical Microbiology, Lund University, Lund, Sweden
###end p 2
###begin p 3
Current address: Malaghan Institute of Medical Research, Wellington, New Zealand
###end p 3
###begin title 4
Background
###end title 4
###begin p 5
Members of the Peroxisome Proliferator Activated Receptor, PPAR, subfamily of nuclear receptors display complex opposing and overlapping functions and a wide range of pharmacological and molecular genetic tools have been used to dissect their specific functions. Non-agonist bound PPARdelta has been shown to repress PPAR Response Element, PPRE, signalling and several lines of evidence point to the importance of PPARdelta repressive actions in both cardiovascular and cancer biology.
###end p 5
###begin title 6
Methodology/Principal Findings
###end title 6
###begin p 7
In this report we have employed transient transfections and luciferase reporter gene technology to study the repressing effects of PPARdelta and two derivatives thereof. We demonstrate for the first time that the classical dominant negative deletion of the Activation Function 2, AF2, domain of PPARdelta show enhanced repression of PPRE signalling in the presence of a PPARdelta agonist. We propose that the mechanism for the phenomenon is increased RXR heterodimerisation and DNA binding upon ligand binding concomitant with transcriptional co-repressor binding. We also demonstrated ligand-dependent dominant negative action of a DNA non-binding derivative of PPARdelta on PPARgamma1 signalling. This activity was abolished upon over-expression of RXRalpha suggesting a role for PPAR/cofactor competition in the absence of DNA binding.
###end p 7
###begin title 8
Conclusions/Significance
###end title 8
###begin p 9
These findings are important in understanding the wide spectrum of molecular interactions in which PPARdelta and PPARgamma have opposing biological roles and suggest novel paradigms for the design of different functional classes of nuclear receptor antagonist drugs.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 436 439 424 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Desvergne1">[1]</xref>
###xml 441 444 429 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Staels1">[2]</xref>
###xml 446 449 434 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Willson1">[3]</xref>
The peroxisome proliferator-activated receptors (PPARs) alpha, delta and gamma belong to the nuclear receptor family of transcriptional regulators. They function as obligate heterodimers with the retinoid X receptors, RXRs, and signal from PPAR response elements (PPREs) upon binding PPAR- and/or RXR agonists. The PPAR ligands consist of naturally occurring fatty acids and fatty acid derivatives as well as a range of synthetic drugs [1], [2], [3].
###end p 11
###begin p 12
###xml 414 417 396 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Desvergne1">[1]</xref>
###xml 419 422 401 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Tachibana1">[4]</xref>
###xml 342 346 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
###xml 351 355 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 401 406 <span type="species:ncbi:9606">human</span>
PPARalpha is involved in the control of catabolic fatty acid metabolism such as peroxisomal beta-oxidation and mitochondrial beta-and omega-oxidation of fatty acids and is most prevalent in metabolically active tissues such as liver. PPARalpha is activated by the blood lipid lowering fibrate drugs. These acts as peroxisome proliferators in mice and rats but no adverse effects have been detected in human livers [1], [4].
###end p 12
###begin p 13
###xml 423 426 411 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Tontonoz1">[5]</xref>
PPARgamma is involved in fatty acid and glucose homeostasis and is required for adipocyte differentiation and for placental development. Activation of PPARgamma also seems to act anti-inflammatory and to hinder proliferation or cause apoptosis in cancer cells. The insulin sensitizing thiazolidinedione drugs, which are high affinity PPARgamma agonists, are used to treat type 2 diabetes and experimentally to treat cancer [5].
###end p 13
###begin p 14
###xml 127 130 123 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Abbott1">[6]</xref>
###xml 412 415 400 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Tachibana1">[4]</xref>
###xml 417 420 405 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Desvergne2">[7]</xref>
###xml 422 425 410 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Seedorf1">[8]</xref>
###xml 427 430 415 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Takahashi1">[9]</xref>
###xml 633 637 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Riserus1">[10]</xref>
###xml 639 643 619 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Sprecher1">[11]</xref>
###xml 525 530 <span type="species:ncbi:9606">human</span>
PPARdelta is widely expressed and the most prevalent PPAR in several tissues both in the adult organism and during development [6]. It is also the least known in terms of biological function, although recent reports would suggest that it might have a role similar to PPARalpha in tissues other than liver. PPARdelta has also been shown to be involved in placental implantation, wound healing, and carcinogenesis [4], [7], [8], [9]. No PPARdelta ligands are currently used as such in treatment of disease, although studies on human subjects for the use of a PPARdelta agonist in the treatment of metabolic syndrome have been reported [10], [11].
###end p 14
###begin p 15
###xml 250 254 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Krogsdam1">[12]</xref>
###xml 256 260 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Shi1">[13]</xref>
###xml 535 539 507 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Shi1">[13]</xref>
###xml 921 925 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Shi1">[13]</xref>
Recently, it was shown that non-liganded PPARdelta attracts transcriptional co-repressors when bound to DNA more effectively than PPARalpha and gamma. Due to its widespread distribution it was suggested that PPARdelta acts as a PPRE gateway receptor [12], [13]. Given the, sometimes conflicting, results on PPARdelta biology obtained using various pharmacological and molecular genetic tools we set out to study the ligand modulated antagonism of PPARgamma1 by genomic and non-genomic actions of PPARdelta. We found in accordance with [13] that non-liganded PPARdelta represses PPARalpha and gamma. In line with this the PPARdelta derivative PPARdeltaDeltaAF2, lacking helix 12 (or activation function 2, AF2), acts dominant negatively on PPARalpha, gamma1 and delta signalling. Furthermore, we found that PPARdeltaDeltaAF2 possess ligand enhanced dominant negative activity on PPRE signalling. In contrast to Shi et al. [13] who reported that a non-DNA binding PPARdelta derivative didn't exert any dominant negative effects, we found that non-DNA bound PPARdelta ligand-binding domain (LBD) exerts ligand-dependent dominant negative activity on PPARgamma1 signalling. Since PPARdelta and gamma co-exist in a range of tissues and in many cases have opposite biological effects we propose that the phenomena discovered might have important implications for PPAR experimental designs, PPAR biology in general and possibly drug design.
###end p 15
###begin title 16
Results and Discussion
###end title 16
###begin title 17
Agonist non-bound PPARdelta is a repressor of PPARgamma1 dependent PPRE signalling, but not vice versa
###end title 17
###begin p 18
###xml 203 211 203 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 265 269 261 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Krogsdam1">[12]</xref>
###xml 271 275 267 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Shi1">[13]</xref>
###xml 682 691 658 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g001">Figure 1A</xref>
###xml 808 817 776 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g001">Figure 1B</xref>
Due to its widespread tissue distribution and the fact that it interacts more efficiently on DNA with nuclear receptor co-repressors than the other PPAR isoforms it was proposed, as well as demonstrated in vitro, that PPARdelta functions as a PPRE gateway receptor [12], [13]. We confirmed this phenomenon for PPARdelta and gamma1 signalling using transient transfection of COS-1 cells with plasmids encoding these PPAR isoforms and a promiscuous (transcriptionally transactivated by all three PPAR isoforms, data not shown for PPARalpha), PPRE luciferase reporter gene construct (pLFABPluc). We found that the presence of unliganded PPARgamma1 did not affect PPARdelta signalling (Figure 1A) whereas unliganded PPARdelta significantly (P<0.001) repressed the PPARgamma1 dependent signalling from pLFABPluc (Figure 1B).
###end p 18
###begin title 19
The effect of (A) non-liganded PPARgamma1 on PPARdelta signalling and of (B) non-liganded PPARdelta on PPARgamma1 signalling.
###end title 19
###begin p 20
COS-1 cells were transiently transfected with (per well in six-well plates) 50 ng (A) pCLDN-hPPARdelta or (B) pCDLN-hPPARgamma1 and 250 ng (A) pCLDN or pCLDN-hPPARgamma1 and (B) pCLDN or pCLDN-hPPARdelta, respectively.
###end p 20
###begin title 21
Ligand-enhanced dominant negative action of PPARdeltaDeltaAF2
###end title 21
###begin p 22
###xml 243 247 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Barroso1">[14]</xref>
###xml 249 253 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Hatae1">[15]</xref>
###xml 255 259 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Michalik1">[16]</xref>
###xml 586 590 566 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-TargettAdams1">[17]</xref>
###xml 827 840 787 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g002">Figure 2A &amp; B</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Helix 12 modifications (both designed and for PPARgamma, found in human patients as mutations) have been shown to render PPARs dominant negative due to their inability to recruit co-activators while retaining the ability to bind co-repressors [14], [15], [16]. Given the superior repressing properties of PPARdelta, modification of helix 12 should render it a relatively effective ligand independent repressor of PPRE signalling. We have previously employed a PPARdelta derivative lacking the C-terminal 11 amino acid residues, PPARdeltaDeltaAF2, as a tool for studying PPRE signalling [17]. In order to further characterize the properties of this construct we conducted a range of transient transfection experiments. PPARdeltaDeltaAF2 was found to act in a dominant negative fashion on PPARalpha, gamma1 and delta signalling (Figure 2A & B, respectively, P<0.001, data not shown for PPARalpha), thus confirming and extending our previous observations.
###end p 22
###begin title 23
PPARdeltaDeltaAF2 represses (A) PPARdelta and (B) PPARgamma1 signalling. (C) PPARdeltaDeltaAF2 represses TK-promoter activity in a ligand-enhanced fashion.
###end title 23
###begin p 24
COS-1 cells were transiently transfected with (per well in six-well plates) (A) 50 ng pCLDN-hPPARdelta or (B) pCDLN-hPPARgamma1 and 250 ng pCLDN or pCLDN-hPPARdeltaDeltaAF2. (C) and (D) T47D cells were transfected with (per well in a six-well plate) 500 ng pCLDN, pCLDN-hPPARdeltaDeltaAF2 or pCLDN-hPPARdelta. (D) is identical to (C) except for the two additional bars representing over-expression of PPARdelta with and without CF.
###end p 24
###begin p 25
###xml 214 217 214 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Willson1">[3]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Forman1">[18]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-He1">[19]</xref>
###xml 902 911 878 887 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g002">Figure 2D</xref>
###xml 1049 1058 1017 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g002">Figure 2C</xref>
###xml 1223 1232 1183 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g002">Figure 2C</xref>
###xml 1745 1749 1681 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Shearer1">[20]</xref>
Upon agonist binding PPARs undergo a conformational change leading to increased RXR heterodimerisation and shedding of transcriptional co-repressors with the subsequent recruitment of transcriptional co-activators [3]. The increased PPAR-RXR heterodimerisation leads to an increased affinity for PPREs [18], [19]. This would in the case of PPARdeltaDeltaAF2 lead to increased occupancy of the PPREs concomitant with recruitment of transcriptional co-repressors and thus further reduced PPRE signalling. We thus investigated the effect of a PPARdelta agonist on the dominant negative properties of PPARdeltaDeltaAF2. Because of the relatively high endogenous PPRE signalling in the COS-1 cells we employed T47D cells grown in RPMI 1640 medium supplemented with 5% dextran charcoal-stripped serum for this experiment. The effect of over-expressing and transactivating PPARdelta in T47D cells is shown in Figure 2D. We could detect a small but significant (P<0.001) PPARdelta (CF dependent) activity in cells with no added PPARdelta expression vector (Figure 2C). We could also see a small but significant (P<0.01) effect of introducing PPARdeltaDeltaAF2 on non-CF dependent transcription of the luciferase gene in pLFABPluc (Figure 2C). The dominant negative effect of introducing PPARdeltaDeltaAF2 into the system was further enhanced by the addition of CF (P<0.001). This indicates that for PPARdeltaDeltaAF2 CF acts as an inverse agonist that enhances the dominant negative effect, a novel concept for type II nuclear receptors. The concept was discussed and investigated for the only PPARdelta antagonist described to date, GSK0660. GSK0660 did not, however, increase occupancy of PPARdelta or transcriptional co-repressors to chromatin PPREs [20].
###end p 25
###begin title 26
The PPARdelta ligand-binding domain is a repressor of PPRE dependent PPARgamma1 signalling in the presence of a PPARdelta agonist
###end title 26
###begin p 27
###xml 224 228 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Ide1">[21]</xref>
###xml 230 234 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Yoshikawa1">[22]</xref>
###xml 264 268 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Matsusue1">[23]</xref>
###xml 314 318 295 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Chu1">[24]</xref>
###xml 370 374 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Ying1">[25]</xref>
###xml 376 380 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Araki1">[26]</xref>
###xml 1099 1108 1033 1042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g003">Figure 3A</xref>
Since the PPARs act as RXR heterodimers it would be conceivable that RXR competition could occur among the PPAR isoforms. In fact, ligand dependent RXR competition has been described for PPARalpha and liver X receptor (LXR) [21], [22], PPARbeta/delta and LXRalpha [23], PPARalpha and thyroid hormone receptor (TR) [24] as well as PPARgamma and TRalpha1 and beta mutants [25], [26]. Agonist-bound wild-type PPARdelta and gamma activate transcription when bound to PPREs. Thus, in order to study the PPRE independent effects of PPARdelta and gamma we needed a non-DNA binding derivative with a functional ligand binding and activating domain. We generated an expression plasmid for the PPARdelta LBD, pCLDN-deltaLBD, and tested it for the desired properties in a mammalian two-hybrid assay. Co-expression of the GAL4-RXRalpha fusion protein and the PPARdelta LBD led to CF induced upstream activating sequence (UAS) dependent transcriptional transactivation, strongly indicating that the PPARdelta LBD is functional with respect to RXR heterodimerisation and transcriptional co-activator recruitment (Figure 3A, P<0.001).
###end p 27
###begin title 28
(A) The PPARdelta LBD is functional with respect to transcriptional transactivation and RXR heterodimerisation and (B), (C) and (D) possess ligand-dependent dominant negative behaviour.
###end title 28
###begin p 29
(A) COS-1 cells were transfected with 500 ng pCMVgRXR and 500 ng pCLDN or pCLDN-deltaLBD. (B), (C) and (D) COS-1 cells were transiently transfected with: (B) 500 ng pJ3Nuc (hPPARdelta expression plasmid) and 0 to 500 ng pCLDN or pCLDN-deltaLBD; (C) 50 ng pCLDN-hPPARgamma1 and 0 to 500 ng pCLDN or pCLDN-deltaLBD; (D) 50 ng pCLDN-hPPARgamma1 and 500 ng pCLDN-deltaLBD.
###end p 29
###begin p 30
###xml 262 272 238 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g003">Figures 3B</xref>
###xml 357 373 333 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g003">Figures 3B and C</xref>
###xml 697 707 649 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g003">Figures 3D</xref>
Subsequent to the functional validation of the PPARdelta LBD we investigated whether it had a dominant negative effect on PPARdelta and gamma1 signalling. We found that PPARdelta but not PPARgamma1 signalling was abolished by co-expression of the PPARdelta LBD (Figures 3B (P<0.001) and C, respectively). One important difference between the experiments in Figures 3B and C is the absence of the CF in 3C. If a PPARdelta agonist is required for efficient RXR heterodimerisation then the addition of CF would render the PPARdelta LBD dominant negative on PPARgamma1 signalling. Indeed, we found that the PPARdelta LBD could repress the PPARgamma1 signalling in the presence of a PPARdelta agonist (Figures 3D, P<0.001).
###end p 30
###begin p 31
###xml 467 482 439 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4A and B</xref>
###xml 593 602 561 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4A</xref>
###xml 787 796 747 756 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4B</xref>
Given the known effects of agonist binding to a PPAR one could speculate whether the dominant negative effect of the PPARdelta LBD is due to RXR or transcriptional co-activator squelching. To address this question we co-expressed RXRalpha and the transcriptional co-activator, steroid receptor co-activator 1a (SRC1a), with PPARdelta and gamma1 with and without the PPARdelta LBD. PPARdelta signalling was found to be repressed by co-expression of the PPARdelta LBD (Figure 4A and B, P<0.001 and P<0.05, respectively). This dominant negative effect was abolished by co-expression of RXRalpha (Figure 4A, P>0.05). Co-expression of SRC1a with PPARdelta increased the agonist dependent inducibility of reporter activity but didn't abolish the effects of PPARdelta LBD dependent repression (Figure 4B).
###end p 31
###begin title 32
The effect of co-expression of RXRalpha and SRC1a on PPARdelta LBD mediated repression of PPARdelta (A and B) and PPARgamma1 (C and D) signalling, respectively.
###end title 32
###begin p 33
COS-1 cells were transfected with: (A and B) 500 ng pJ3Nuc and the following plasmids: 500 ng pCLDN or pCLDN-deltaLBD and pCLDN or (A) pSG-mRXRalpha or (B) pSG5-SRC1a and for (C and D) 50 ng pCLDN-hPPARgamma1 and the following plasmids: 500 ng pCLDN or pCLDN-deltaLBD and 500 ng pCLDN or (C) pSG-mRXRalpha or (D) pSG5-SRC1a.
###end p 33
###begin p 34
###xml 237 253 221 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figures 4C and D</xref>
###xml 388 404 364 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figures 4C and D</xref>
###xml 668 677 628 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4C</xref>
###xml 811 820 767 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>
###xml 937 946 885 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>
###xml 1046 1055 990 999 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>
###xml 1285 1294 1217 1226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>
###xml 1378 1387 1306 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0007046-g004">Figure 4D</xref>
###xml 1765 1772 1673 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
We then proceeded to study the effect of RXRalpha and SRC1a co-expression on the effect of the PPARdelta LBD on PPARgamma1 signalling. In this experimental setup the PPARdelta LBD showed dominant negative behaviour in the absence of CF (Figures 4C and D, P<0.001 and P<0.05, respectively). The dominant negative effect of the PPARdelta LBD was somewhat enhanced by the PPARdelta agonist (Figures 4C and D). The effect of co-expression of RXRalpha was similar to that of the PPARdelta experiment with overall activity somewhat increased but with lower levels of PPARgamma agonist dependent induction and in abolishing the dominant negative effect of the PPARdelta LBD (Figure 4C). Co-expression of SRC1a increased the level of activity of PPARgamma1 without having a much of an effect on the level of induction (Figure 4D). The PPARdelta LBD repressed PPARgamma1 signalling (P<0.05) with additional repression seen in the presence of CF (Figure 4D). As was the case for PPARdelta, the addition of SRC1a increased the overall levels of signalling (Figure 4D). Also similarly with the SRC1a co-expression experiment with PPARdelta the addition of SRC1a did not abolish the PPARdelta LBD mediated repression. Instead, the level of PPARdelta LBD mediated repression became more pronounced (Figure 4D, P<0.001). Furthermore, the PPARdelta agonist enhanced repression was more marked (Figure 4D, P<0.05). Since the addition of RXRalpha seems to relieve the PPARdelta LBD mediated repression of PPARdelta and PPARgamma1 signalling whereas the addition of SRC1a still allows the PPARdelta LBD mediated repression we conclude that RXR sequestration is likely to be the main mechanism behind the phenomenon. We thus speculate that ligand dependent RXR competition could occur in vivo between at least PPARdelta and PPARgamma and quite possible between all three PPAR isoforms.
###end p 34
###begin title 35
Concluding remarks
###end title 35
###begin p 36
The major conclusion we draw from this study is that care must be taken when interpreting results obtained from all genetic models of PPARdelta action. The genetic ablation of PPARdelta will remove both the ability to activate PPARdelta, but also the intrinsic role that PPARdelta has in the tempering of PPARalpha and PPARgamma signalling. Therefore it is prudent to use a wide range of both gain and loss of function experiments in order to fully understand the function of PPARdelta and its relationship to PPARalpha and PPARgamma signalling. This is most likely to be true for other nuclear receptors forming heterodimers with RXRs as well.
###end p 36
###begin p 37
Our study also might suggest a novel paradigm for the design of different functional classes of type II nuclear receptor antagonist drugs. One could envisage two sets of nuclear receptor antagonists with very different biological actions (simplistically stating the two extremes of antagonist behaviour); one that displaces the PPAR/RXR complex from the PPRE and one that simultaneously increases DNA binding and transcriptional co-repressor recruitment.
###end p 37
###begin title 38
Materials and Methods
###end title 38
###begin title 39
Cloning and plasmids
###end title 39
###begin p 40
###xml 51 55 51 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Sambrook1">[27]</xref>
###xml 163 179 163 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 111 116 <span type="species:ncbi:9606">Human</span>
###xml 163 179 <span type="species:ncbi:562">Escherichia coli</span>
General DNA techniques were performed according to [27]. DNA sequencing was done by the DNA Analysis Facility, Human Genetics Unit, at Ninewells Hospital, Dundee. Escherichia coli XL1 Blue was transformed according to the manufacturer's instructions (Stratagene).
###end p 40
###begin p 41
###xml 222 226 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-TargettAdams1">[17]</xref>
###xml 228 232 208 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Adamson1">[28]</xref>
###xml 234 238 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Schmidt1">[29]</xref>
###xml 240 244 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Solomin1">[30]</xref>
###xml 246 250 226 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Allenby1">[31]</xref>
###xml 252 256 232 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Kalkhoven1">[32]</xref>
###xml 258 262 238 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Vosper1">[33]</xref>
###xml 363 372 340 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPAR&#948;</italic>
###xml 503 509 476 482 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</underline>
###xml 509 512 482 485 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ATG</bold>
###xml 497 536 470 509 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGG<underline>GGTACC</underline><bold>ATG</bold>GCTATCCGTTTTGGTCGGATG-3&#8242;</named-content>
###xml 555 561 528 534 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GGTACC</underline>
###xml 549 589 522 562 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CGG<underline>GGTACC</underline>TTAGTACATGTCCTTGTAGATCTCC-3&#8242;</named-content>
###xml 592 595 565 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kpn</italic>
###xml 620 623 593 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Kpn</italic>
###xml 667 671 640 644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Aiyar1">[34]</xref>
###xml 813 816 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sal</italic>
###xml 818 821 787 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 842 846 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Solomin1">[30]</xref>
###xml 946 949 915 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Xho</italic>
###xml 357 362 <span type="species:ncbi:9606">human</span>
The expression plasmids pCLDN-hPPARdelta (pMGD60), pCLDN-hPPARdeltaDeltaAF2, pCLDN-hPPARgamma1, pJ3NUC, pCMVg-RXR, pSG-mRXRalpha and pSG5-SRC1a as well as the PPRE reporter plasmid pLFABPluc have been described previously [17], [28], [29], [30], [31], [32], [33]. The internal transfection control plasmid pSVbeta-galactosidase is from Promega. The part of human PPARdelta encoding the LBD (from codon A142, including an added translational start codon, in bold) was amplified with primers PRMG4 (5'-CGGGGTACCATGGCTATCCGTTTTGGTCGGATG-3') and PRMG5 (5'-CGGGGTACCTTAGTACATGTCCTTGTAGATCTCC-3') (KpnI-sites underlined). The KpnI cleaved PCR product was cloned into pCLDN [34], creating pCLDN-deltaLBD (confirmed by sequencing). A GAL4-fusion luciferase reporter plasmid (p4xUAS-TK-luc) was constructed by cloning the SalI-XhoI fragment of pLacZr [30] (containing the 4xUAS-TK, Upstream Activating Sequence) module in pGL3basic (Promega) cleaved with XhoI.
###end p 41
###begin title 42
Growth of cells and transient transfections
###end title 42
###begin p 43
###xml 86 87 86 87 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 563 567 553 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Cullen1">[35]</xref>
###xml 687 691 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Vosper1">[33]</xref>
###xml 751 755 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Lehmann1">[36]</xref>
###xml 163 169 <span type="species:ncbi:9913">bovine</span>
###xml 422 428 <span type="species:ncbi:9913">bovine</span>
COS-1 and T47D cells (Cancer Research U. K. cell resources unit) were grown in a 5% CO2 atmosphere at 37degreesC in high glucose DMEM supplemented with 10% foetal bovine serum and 50 U/ml penicillin G and 50 microg/ml streptomycin (Gibco) and 2 mM L-glutamine for COS-1 and T47D cells, respectively. For transfections the T47D cells were grown in RPMI 1640 (phenol red-free) containing 5% dextran-charcoal stripped foetal bovine serum. Transient transfections of COS-1 cells and T47D cells were performed in six-well plates using DEAE-dextran according to Cullen [35] and Lipofectamine 2000 (Invitrogen), respectively. 24 hours post transfection, medium containing 50 nM compound F, CF, [33] for PPARdelta activation and/or 500 nM rosiglitazone, BRL, [36] for PPARgamma1 activation in a final concentration of 0.1% dimethyl sulfoxide (DMSO) or DMSO alone was added. 48 hours post transfection cell lysates were generated using Promega's reporter lysis buffer.
###end p 43
###begin p 44
###xml 331 335 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0007046-Sambrook1">[27]</xref>
For all transfections 500 ng luciferase reporter (pLFABPluc or p4xUAS-TK-luc) and 50 ng pSVbeta-galactosidase were used per well in six-well plates. Luciferase activity was assayed with the Promega luciferase assay substrate and beta-galactosidase activity according to Sambrook et al. using o-nitrophenyl-beta-D-galactopyranoside [27] or using the chemiluminescent beta-gal reporter gene assay kit from Roche.
###end p 44
###begin title 45
Statistical analysis
###end title 45
###begin p 46
Relative reporter gene expression is stated as the luciferase activity normalized against the corresponding beta-galactosidase activity. These values have in turn been normalised against the mean of the normalized luciferase activities of the leftmost bars in each graph. Each experiment was repeated three times and the bars in the graphs represent the means and the error bars represent the standard error of the mean. One-way ANOVA was performed on the data from each experiment and the Newman-Keuls test was employed for calculating statistical significance using GraphPad Prism 3 software.
###end p 46
###begin title 47
References
###end title 47
###begin article-title 48
Peroxisome proliferator-activated receptors: nuclear control of metabolism.
###end article-title 48
###begin article-title 49
Therapeutic roles of peroxisome proliferator-activated receptor agonists.
###end article-title 49
###begin article-title 50
The PPARs: from orphan receptors to drug discovery.
###end article-title 50
###begin article-title 51
The Role of PPARs in Cancer.
###end article-title 51
###begin article-title 52
Fat and beyond: the diverse biology of PPARgamma.
###end article-title 52
###begin article-title 53
###xml 145 150 <span type="species:ncbi:9606">human</span>
Review of the expression of peroxisome proliferators-activated receptors alpha (PPARalpha), beta (PPARbeta), and gamma (PPARgamma) in rodent and human development.
###end article-title 53
###begin article-title 54
Transcriptional regulation of metabolism.
###end article-title 54
###begin article-title 55
Emerging roles of PPARdelta in metabolism.
###end article-title 55
###begin article-title 56
New therapeutic target for metabolic syndrome: PPARdelta.
###end article-title 56
###begin article-title 57
###xml 205 208 <span type="species:ncbi:9606">men</span>
Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.
###end article-title 57
###begin article-title 58
Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist.
###end article-title 58
###begin article-title 59
Nuclear receptor corepressor-dependent repression of peroxisome-proliferator-activated receptor delta-mediated transactivation.
###end article-title 59
###begin article-title 60
The peroxisome proliferator-activated receptor delta, an integrator of transcriptional repression and nuclear receptor signaling.
###end article-title 60
###begin article-title 61
###xml 31 36 <span type="species:ncbi:9606">human</span>
Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension.
###end article-title 61
###begin article-title 62
Prostacyclin-dependent apoptosis mediated by PPARdelta.
###end article-title 62
###begin article-title 63
Selective expression of a dominant-negative form of peroxisome proliferator-activated receptor in keratinocytes leads to impaired epidermal healing.
###end article-title 63
###begin article-title 64
###xml 64 69 <span type="species:ncbi:9606">human</span>
A PPAR response element regulates transcription of the gene for human adipose differentiation-related protein.
###end article-title 64
###begin article-title 65
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta.
###end article-title 65
###begin article-title 66
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.
###end article-title 66
###begin article-title 67
Identification and characterization of a selective peroxisome proliferator-activated receptor beta/delta (NR1C2) antagonist.
###end article-title 67
###begin article-title 68
Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling.
###end article-title 68
###begin article-title 69
Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. I. PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling.
###end article-title 69
###begin article-title 70
Ligand-activated PPARbeta efficiently represses the induction of LXR-dependent promoter activity through competition with RXR.
###end article-title 70
###begin article-title 71
Thyroid hormone (T3) inhibits ciprofibrate-induced transcription of genes encoding beta-oxidation enzymes: cross talk between peroxisome proliferator and T3 signaling pathways.
###end article-title 71
###begin article-title 72
Impaired adipogenesis caused by a mutated thyroid hormone alpha1 receptor.
###end article-title 72
###begin article-title 73
Thyroid hormone receptor beta mutants: Dominant negative regulators of peroxisome proliferator-activated receptor gamma action.
###end article-title 73
###begin article-title 74
Molecular Cloning: A laboratory Manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press.
###end article-title 74
###begin article-title 75
Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling.
###end article-title 75
###begin article-title 76
Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.
###end article-title 76
###begin article-title 77
Retinoid-X receptor signalling in the developing spinal cord.
###end article-title 77
###begin article-title 78
Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids.
###end article-title 78
###begin article-title 79
Isoforms of steroid receptor co-activator 1 differ in their ability to potentiate transcription by the oestrogen receptor.
###end article-title 79
###begin article-title 80
###xml 84 89 <span type="species:ncbi:9606">human</span>
The peroxisome proliferator-activated receptor delta promotes lipid accumulation in human macrophages.
###end article-title 80
###begin article-title 81
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human AT1 receptor is a single copy gene: characterization in a stable cell line.
###end article-title 81
###begin article-title 82
Use of eukaryotic expression technology in the functional analysis of cloned genes.
###end article-title 82
###begin article-title 83
An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma).
###end article-title 83
###begin p 84
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 84
###begin p 85
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This study was financed by the Medical Research Council Career Development Award G0000119 (). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 85

